Table 4 Time to onset of eptinezumab-associated adverse events and Weibull distribution analysis.
From: Comprehensive safety analysis of adverse events associated with eptinezumab in migraine treatment
Drug | TTO(days) | Weibull distribution | |||
|---|---|---|---|---|---|
Case reports | Median(d)(IQR) | Scale parameter: α(95%CI) | Shape parameter: β(95%CI) | Type | |
Eptinezumab | 639 | 52 (6–145) | 75.20 (65.26–85.15) | 0.62 (0.58–0.66) | Early failure |
